USA flag logo/image

An Official Website of the United States Government

MOLECULAR DIAGNOSTICS FOR EPSTEIN-BARR VIRUS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
2919
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
2919
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Molecular Diagnostic Systems
4 Research Ct Rockville, MD 20850
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1988
Title: MOLECULAR DIAGNOSTICS FOR EPSTEIN-BARR VIRUS
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

EPSTEIN-BARR VIRUS (EBV) CAUSES MONONUCLEOSIS, IS STRONGLY IMPLICATED IN BURKITT'S LYMPHOMA AND NASOPHARYNGEAL CARCINOMA, AND MAY BE ASSOCIATED WITH RHEUMATOID ARTHRITIS. INDIVIDUALS WITH THESE DISEASES PRODUCE ANTIBODIES TO VIRAL EARLY ANTIGENS, CAPSID ANTIGENS, AND NUCLEAR ANTIGENS. THE IMMUNE RESPONSE TO EBV ANTIGENS HAS BEEN SHOWN TO BE AN IMPORTANT INDICATOR FOR CLINICAL EVALUATION AND TREATMENT. HOWEVER, CURRENT IMMUNE ASSAYS LACK SENSITIVITY AND SELECTIVITY, REQUIRE EXPERT INTERPRETATION, AND ARE NOT AMENABLE TO LARGE-SCALE CLINICAL STUDIES. OUR GOAL IS TO IMPROVE THE CLINICAL DIAGNOSTICS FOR EBV-RELATED DISEASES. GENES FOR EBV ANTIGENS WERE CLONED INTO A HIGH EXPRESSION PLASMID AND THE CORRESPONDING EBV POLYPEPTIDES WERE SYNTHESIZED IN BACTERIA, PURIFIED, AND USED TO DEVELOP SENSITIVE ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) IN THE PROPOSED RESEARCH, THESE ELISA METHODS WILL BE USED TO MEASURE CLASS-SPECIFIC (IGG, IGA, IGM) ANTIBODY TITERS TO EBV ANTIGENS IN NORMAL INDIVIDUALS AND IN PATIENTS WITH ACUTE AND CHRONIC MONONUCLEOSIS, BURKITT'S LYMPHOMA, NASOPHARYNGEAL CARCINOMA, AND RHEUMATOID ARTHRITIS. THE SPECIFIC ANTIBODY LEVELS WILL BE CORRELATED WITH CLINICAL DATA TO DETERMINE THE EFFICACY OF THE ELISA MEASUREMENTS AS PROGNOSTIC INDICATORS. IN THE INITIAL STUDIES OF PHASE I, THE ANALYSIS WILL BE LIMITED TO SAMPLES FROM SERUM BANKS. IF THE DATA SUPPORT THE CLINICAL VALUE OF THE ASSAYS, PHASE II STUDIES WILL ENTAIL FIELD TRIALS INVOLVING CLOSE COLLABORATION WITH CLINICIANS.

Principal Investigator:

Alan L. Scott
Principal Investigator
3019553442

Business Contact:

Small Business Information at Submission:

Molecular Diagnostic Systems,
3100 Wyman Park Drive Baltimore, MD 21211

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No